Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Tarantelli

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Blood Advances|May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsAfua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
Biosensors & Bioelectronics: X|January 2, 2023
A DNA biosensors-based microfluidic platform for attomolar real-time detection of unamplified SARS-CoV-2 virusPerrine Robin, Laura Barnabei, Stefano Marocco, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Haematologica|August 5, 2018
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphomaAfua A Mensah, Luciano Cascione, Eugenio Gaudio, et al.
British Journal of Haematology|November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisibGiulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted DrugsMichela Boi, Eugenio Gaudio, Paola Bonetti, et al.
Blood Advances|September 4, 2020
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734Filippo Spriano, Eugenio Gaudio, Luciano Cascione, et al.
ESMO Open|October 12, 2018
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistanceChiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, et al.
Cancer Research Communications|April 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune ToleranceZoë Johnson, Chiara Tarantelli, Elisa Civanelli, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Blood Advances|May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsAfua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
Biosensors & Bioelectronics: X|January 2, 2023
A DNA biosensors-based microfluidic platform for attomolar real-time detection of unamplified SARS-CoV-2 virusPerrine Robin, Laura Barnabei, Stefano Marocco, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Haematologica|August 5, 2018
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphomaAfua A Mensah, Luciano Cascione, Eugenio Gaudio, et al.
British Journal of Haematology|November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisibGiulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted DrugsMichela Boi, Eugenio Gaudio, Paola Bonetti, et al.
Blood Advances|September 4, 2020
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734Filippo Spriano, Eugenio Gaudio, Luciano Cascione, et al.
ESMO Open|October 12, 2018
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistanceChiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, et al.
Cancer Research Communications|April 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune ToleranceZoë Johnson, Chiara Tarantelli, Elisa Civanelli, et al.
Pageof 6